Watch GALT. Know when insiders buy.
One email the day a filing lands. Free.
GALT
GALECTIN THERAPEUTICS INC
3.73
−0.11 −2.86%
USD · close Sep 15
A free account adds a watchlist, alerts when insiders, Congress or short sellers move on your tickers, and a morning brief. Sign up
Work order
48
WATCH · shorts 48
Insiders, 90 days
0
no open-market filings in 90 days
Congress, 90 days
0 / 0
no disclosures naming it
Big money
0 / 15
none of the tracked funds disclose it
Calls on record
0
nobody we score has called it yet
MKT CAP $376.2MP/E —DIV YIELD —FCF YIELD —REV TTM —NET INCOME −$27.8MNET CASH —52W 2.08 – 6.51SEC XBRL · TTM TO Invalid Date
Financials
By quarter
| Period | Revenue | YoY | Gross margin | Operating income | Net income | YoY | EPS | Op. cash flow | Capex | Free cash flow | Filed |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Q2 2026 · Jun 30 | — | — | — | −$4M | −$9.1M | — | -0.14 | −$2.4M | — | — | Aug 14 |
| Q1 2026 · Mar 31 | — | — | — | −$4.1M | −$5M | — | -0.08 | −$3.9M | — | — | May 15 |
| Q4 2025 · Dec 31derived | — | — | — | −$3.4M | −$5.5M | — | -0.08 | −$6M | — | — | Mar 31 |
| Q3 2025 · Sep 30 | — | — | — | −$4.2M | −$8.2M | — | -0.13 | −$3.5M | — | — | Nov 14 |
| Q2 2025 · Jun 30 | — | — | — | −$4.6M | −$7.5M | — | -0.12 | −$6.6M | — | — | Aug 14 |
| Q1 2025 · Mar 31 | — | — | — | −$7.9M | −$9.6M | — | -0.15 | −$7.7M | — | — | May 15 |
| Q4 2024 · Dec 31derived | — | — | — | −$12.4M | −$12M | — | -0.19 | −$12.8M | — | — | Mar 31 |
| Q3 2024 · Sep 30 | — | — | — | −$9.1M | −$11.2M | — | -0.18 | −$8.5M | — | — | Nov 14 |
| Q2 2024 · Jun 30 | — | — | — | −$11.3M | −$12.4M | — | -0.20 | −$8.3M | — | — | Aug 14 |
| Q1 2024 · Mar 31 | — | — | — | −$9.6M | −$11.5M | — | -0.19 | −$12.1M | — | — | May 15 |
| Q4 2023 · Dec 31derived | — | — | — | −$9.6M | −$10M | — | -0.16 | −$4.7M | — | — | Mar 31 |
| Q3 2023 · Sep 30 | — | — | — | −$9.2M | −$10.4M | — | -0.24 | −$7.6M | — | — | Nov 14 |
By fiscal year
| Year | Revenue | Gross margin | Operating income | Net income | Net margin | EPS | Op. cash flow | Capex | Free cash flow | Buybacks | Dividends paid |
|---|---|---|---|---|---|---|---|---|---|---|---|
| FY2025 · to Dec 31 | — | — | −$20.1M | −$30.8M | — | -0.48 | −$23.9M | — | — | — | — |
| FY2024 · to Dec 31 | — | — | −$42.4M | −$47M | — | -0.76 | −$41.8M | — | — | — | — |
| FY2023 · to Dec 31 | — | — | −$38.1M | −$41.1M | — | -0.74 | −$33M | — | — | — | — |
| FY2022 · to Dec 31 | — | — | −$38.4M | −$38.8M | — | -0.65 | −$31.1M | — | — | — | — |
| FY2021 · to Dec 31 | — | — | −$30.2M | −$30.5M | — | -0.52 | −$24.3M | — | — | — | — |
| FY2020 · to Dec 31 | — | — | −$23.4M | −$23.5M | — | -0.41 | −$20.6M | — | — | — | — |
Every number comes from GALECTIN THERAPEUTICS INC's own XBRL-tagged filings with the SEC, not a data vendor. Quarters marked derived are the fiscal year minus the three reported quarters, the same way every data provider computes Q4. Restated figures replace originals as later filings arrive.